RxDoctor Payments Data

Shahzad Zaki, MD

Family Medicine · Wallingford, CTNPI 1669706578

Payments from drug & device makers

$357in general payments, 2019–2025

Across 20 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$74
  • MDD US Operations, LLC$73
  • Genentech USA, Inc.$37
  • Lupin Inc.$30
  • Johnson & Johnson$28
  • Neurocrine Biosciences, Inc.$24
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$357 in reported general payments places this provider in the 55th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$613,322
Medicare patients
2,307
Services billed
9,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,567$550,021
NuplazidPimavanserin Tartrate126$248,790
IngrezzaValbenazine Tosylate35$217,022
XifaxanRifaximin150$153,978
TrulicityDulaglutide153$130,766
XareltoRivaroxaban625$129,598
OzempicSemaglutide100$111,138
Abiraterone Acetate13$107,715
JardianceEmpagliflozin473$99,072
AustedoDeutetrabenazine44$98,936
LinzessLinaclotide148$86,660
TradjentaLinagliptin492$81,907
ProcritEpoetin Alfa28$74,832
FarxigaDapagliflozin Propanediol358$73,048
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$64,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$24$217,02235 claims
Johnson & JohnsonXarelto, Procrit$28$204,431653 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$23$134,85171 claims
Otsuka America Pharmaceutical, Inc.Rexulti$24$64,213112 claims
Astellas Pharma US IncMyrbetriq$14$49,372304 claims
NovartisEntresto$13$38,139218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →